Apricus Biosciences News

0,204 -10,53% -0,024 €
10:02 Uhr Stuttgart | Mehr Kurse »
WKN: A2AT45
ISIN: US03832V3078
US-Symbol: APRI
Typ: Aktie

Apricus Biosciences News

16.04.18 Apricus Biosciences Announces Outcome of Vitaros(TM) End-​of-Review Meeting with FDA GlobeNewswire
28.03.18 Apricus Biosciences Announces Pricing of $3.55 Million Public Offering GlobeNewswire
27.03.18 Apricus Biosciences Announces Proposed Public Offering GlobeNewswire
26.03.18 Apricus Biosciences Announces Scheduling of Vitaros(TM) End-​of-Review Meeting with FDA GlobeNewswire
01.03.18 Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
21.02.18 Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call GlobeNewswire
16.02.18 Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM) GlobeNewswire
26.10.17 Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call GlobeNewswire
10.10.17 Apricus Biosciences to Present at the 2017 BIO Investor Forum GlobeNewswire
11.09.17 Apricus Biosciences Announces $3.7 Million Private Placement Priced At-​The-Market GlobeNewswire
05.09.17 Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
31.08.17 Apricus Biosciences Announces FDA Acknowledgement of Vitaros(TM) Class 2 NDA Resubmission GlobeNewswire
29.08.17 Apricus Biosciences Files NDA Resubmission for Vitaros(TM) GlobeNewswire
02.08.17 Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results GlobeNewswire
26.07.17 Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call GlobeNewswire
11.05.17 Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results GlobeNewswire
04.05.17 Apricus Biosciences Announces the Initiation of Vitaros Drug-​Device Human Factors Study GlobeNewswire
04.05.17 Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call GlobeNewswire
02.05.17 Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements GlobeNewswire
21.04.17 Apricus Biosciences Announces Pricing of $7.0 Million Public Offering GlobeNewswire
13.03.17 Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
09.03.17 Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call GlobeNewswire
08.03.17 Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals GlobeNewswire
09.02.17 Apricus Biosciences Receives Positive Nasdaq Listing Determination GlobeNewswire
08.02.17 Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference GlobeNewswire
18.01.17 Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico GlobeNewswire
03.01.17 Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel GlobeNewswire
27.12.16 Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals GlobeNewswire
01.12.16 Apricus Biosciences Receives Nasdaq Compliance Notice GlobeNewswire
29.11.16 Apricus Biosciences to Present at the 9th Annual LD Micro Main Event GlobeNewswire
18.11.16 Apricus Biosciences Provides Update on Vitaros NDA Following Receipt of FDA Feedback GlobeNewswire
20.10.16 Apricus Biosciences Announces 1-for-10 Reverse Stock Split GlobeNewswire
20.10.16 Apricus Biosciences Announces 1-for-10 Reverse Stock Split GlobeNewswire
12.10.16 Apricus Biosciences to Present at the 2016 BIO Investor Forum GlobeNewswire
29.09.16 Apricus Biosciences Closes $3.7 Million Registered Direct Offering GlobeNewswire
23.09.16 Apricus Biosciences Announces $4.6 Million Registered Direct Offering GlobeNewswire
21.09.16 Apricus Biosciences Announces the Launch of Vitaros® in the Czech Republic and Slovakia by Recordati GlobeNewswire
20.09.16 Apricus Biosciences Announces Completion of Transfer of the Marketing Authorizations for Vitaros® in Finland and Denmark to Ferring Pharmaceuticals GlobeNewswire
08.09.16 Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Argentina GlobeNewswire
07.09.16 Apricus Biosciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference GlobeNewswire
06.09.16 Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Portugal, Ireland and Poland by Recordati GlobeNewswire
15.08.16 Apricus Biosciences Announces Completion of Transfer of the United Kingdom Marketing Authorization for Vitaros® to Ferring Pharmaceuticals GlobeNewswire
10.08.16 Apricus Biosciences Announces Completion of Transfer of Vitaros® German Marketing Authorization to Ferring Pharmaceuticals GlobeNewswire
04.08.16 Apricus Biosciences Provides Corporate Update and Second Quarter Financial Results GlobeNewswire
04.08.16 Apricus Biosciences to Present at the Canaccord Genuity 36th Annual Growth Conference GlobeNewswire
01.08.16 Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call GlobeNewswire
27.07.16 Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon GlobeNewswire
25.07.16 Apricus Biosciences, Inc. : Apricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring Pharmaceuticals in Europe and Asia GlobeNewswire
06.07.16 Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital GlobeNewswire
09.05.16 Apricus Biosciences Provides Corporate Update and First Quarter Financial Results GlobeNewswire

Newssuche